Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial
- Reversal by verapamil of defect in sodium transport in leucocytes in essential hypertension. Gray, H.H.; Poston, L.; Hilton, P.J.; Smith, S.J.; Markandu, N.D.; MacGregor, G.A. // British Medical Journal (Clinical Research Edition);3/3/1984, Vol. 288 Issue 6418, p673
Examines the effect of treatment with verapamil on cell sodium transport in the leucocytes of patients with essential hypertension. Abnormalities of sodium efflux rate constant and intracellular sodium content; Sensitive of the efflux rate to ouabain; Reversal of the abnormalities and reduction...
- Hypertension -- Treatment. // Current Medical Literature: Nephrology & Hypertension;2006, Vol. 12 Issue 3, p96
The article presents information on various studies about the treatment of hypertension. A study compares the control of hypertension and the risk of adverse clinical outcomes in Hispanic individuals and non-Hispanic individuals enrolled in International Verapamil-Trandolapril Study. One study...
- Hypertension. // Geriatrics;Feb99, Vol. 54 Issue 2, p14
Reports on the approval of a time-release formulation of verapamil hydrogen chloride (HCl) (Verelan PM) by the United States Food and Drug Administration (FDA) for the management of essential hypertension. Common adverse effects of verapamil on patients with mild to moderate hypertension.
- Controlled-onset calcium antagonist. // Geriatrics;Sept96, Vol. 51 Issue 9, p16
Announces the approval of the extended-release formulation of verapamil HCl (Covera-HS) for the treatment of hypertension and angina. Mechanism of action of verapamil HCl; Most frequent adverse event during clinical trials of verapamil HCl.
- Intoxication volontaire au vérapamil et au bisoprolol : à propos d'un cas. Campergue, Jean-Baptiste; Narci, Clément; Citterio-Quentin, Antony; Faucher, Etienne; Robert, Jean-Michel; Argaud, Laurent; Moulsma, Mustapha // Annales de Toxicologie Analytique;2012, Vol. 24 Issue 2, p103
Objective: Primary essential high blood pressure is treated by different cardiotropic drugs which have similar toxicological effects. Our study is about a verapamil and bisoprolol poisoning, which was at first labelled as bisoprolol only, after a comprehensive toxicological analysis. Materials...
- Comparative release profile of sustained release matrix tablets of verapamil HCI. Mathur, Vikas; Nagpal, Kalpana; Singh, Shailendra Kumar; Mishra, Dina Nath // International Journal of Pharmaceutical Investigation;Jan-Mar2013, Vol. 3 Issue 1, p60
Introduction: Verapamil hydrochloride (VH) is a calcium channel blocking agent used in the treatment of hypertension, cardiac arrhythmia and angina pectoris. The short half-life and high frequency of administration of VH makes it a suitable candidate for designing sustained drug delivery system....
- verapamil. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p786
An encyclopedia entry for "verapamil" is presented. It is a drug that acts as a calcium channel blocker and is used to treat ailments such as hypertension, angina pectoris or chest pain, and certain heartbeat abnormalities. Headache, flushing, dizziness and swelling of the ankles are its...
- Verapamil that listens to your body clock. Cerrato, Paul L. // RN;Aug96, Vol. 59 Issue 8, p64
Introduces the controlled-onset, extended release verapamil. Mechanism of action; Dosage; Common adverse reactions.
- � blockers and calcium antagonists equally effective for hypertension. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);12/6/2003, Vol. 327 Issue 7427, p1305
Reports research showing outcomes are similar in hypertensive patients with coronary artery disease who use a � blocker or calcium antagonist for primary control of blood pressure. Details of the study by Dr. Carl Pepine of the University of Florida College of Medicine, Gainsville and...